Federated Hermes, Inc. Akero Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $2.01 Million - $3.1 Million	-54,420 Reduced 93.82%	3,584 $167,000
Q1 2023 May 08, 2023	SELL	$37.27 - $50.24 $745 - $1,004	-20 Reduced 0.03%	58,004 $2.22 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $1.94 Million - $3.18 Million	58,024 New	58,024 $3.18 Million
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $1.02 Million - $1.92 Million	128,073 Added 914807.12%	128,087 $1.21 Million
Q1 2022 May 13, 2022	BUY	$12.97 - $22.26 $181 - $311	14 New	14 $1,000
Q1 2021 May 13, 2021	SELL	$24.04 - $34.19 $789,233 - $1.12 Million	-32,830 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$25.12 - $29.89 $145,369 - $172,973	-5,787 Reduced 14.99%	32,830 $847,000
Q3 2020 Nov 12, 2020	BUY	$30.79 - $39.92 $1.19 Million - $1.54 Million	38,538 Added 48782.28%	38,617 $1.19 Million
Q2 2020 Aug 13, 2020	BUY	$19.25 - $26.76 $1,520 - $2,114	79 New	79 $2,000

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.